Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP

Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP

Penn Medicine Abramson Cancer Center, University of Pennsylvania School of Nursing

Victoria Sherry,

DNP, CRNP, ANP-BC, AOCNP

Penn Medicine Abramson Cancer Center, University of Pennsylvania School of Nursing

Victoria Sherry holds a dual appointment at the Abramson Cancer Center Penn Medicine as an adult oncology nurse practitioner for thoracic malignancies and as an advanced senior lecturer in the school of nursing, where she teaches both undergraduate and graduate students. She completed her Masters in Nursing at the University of Pennsylvania and her Doctor of Nursing Practice at Duke University. Victoria is a member of the Oncology Nursing Society (ONS) and the Philadelphia Area Chapter of the ONS, as well as the Xi Chapter of Sigma Theta Tau, the honor society of nursing. Throughout her career, Victoria has developed numerous presentations, webinars, and podcasts focused on the clinical knowledge of treatments and supportive care for patients with lung cancer. She is widely published on multiple topics, with a focus on symptom and toxicity management in lung cancer. This is a test.

Victoria's Shared Resources

MARIPOSA-2 and FLAURA2 Trials: Breakthroughs in NSCLC Treatment

The ESMO Asia Congress 2023 highlighted two significant studies on EGFR mutations in non-small cell lung cancer (NSCLC)....
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

FDA Approval of Repotrectinib in Adult Patients Who Have Locally Advanced or Metastatic ROS1-Positive NSCLC

This article highlights the FDA approval of repotrectinib for adults with advanced ROS1-positive non-small cell lung cancer, based on the...
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

American Cancer Society Lung Cancer Screening Guideline Update

The American Cancer Society has updated its lung cancer screening guideline to reduce deaths from the disease, particularly among those...
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

Pfizer Gains FDA Approval for BRAFTOVI® + MEKTOVI® in Treating BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. announced that the FDA approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for treating adult patients with metastatic non-small cell...
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

Study Shows Link Between Incidental Lung CT Findings and Respiratory Disease Mortality

Researchers of a study analyzed data from the National Lung Screening Trial to investigate the connection between incidental respiratory findings...
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP

Study Reveals Shifting Trends in US Cancer Incidence and Mortality

In a study, researchers reviewed American Cancer Society data on cancer cases and deaths in the United States. The study...
CURATED BY:
Victoria Sherry,
DNP, CRNP, ANP-BC, AOCNP
Share